Alcon Commences Phase 2 Clinical Trial of NovaBay’s NVC-422 for Viral Conjunctivitis
July 5, 2009 by Ann Deters
Filed under Alcon
EMERYVILLE, Calif. & HUENENBERG, Switzerland–(BUSINESS WIRE)–Jul. 5, 2009–
Alcon, Inc. (NYSE: ACL)
and its partner, NovaBay Pharmaceuticals, Inc. (NYSE-AMEX: NBY),
announced today that Alcon has begun treating patients in a Phase 2
clinical trial of NovaBay’s patented lead Aganocide®
compound, NVC-422, for viral conjunctivitis, a type of “pink eye.”
Conjunctivitis is a pervasive and painful condition that affects both
adults and children, leading to more than four million doctor and
emergency room visits in the United States each year.
NovaBay has a licensing and research collaboration agreement with Alcon,
…
 |
A post by "Ann Deters" http://www.VantageOutsourcing.com Ann Deters passion is to be an advocate for hospitals and surgery centers, allowing them to maximize profits by providing cataract outsourcing services in an efficient and low cost manner. Ann, has been a columnist about health care issue for two decades writing for numerous health care magazines. |
